Evidence mapPaperPMID 41553702Full record

Trial reportPharmacoEconomics2026

Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial.

Martin Bøg, Anders Bo Bojesen, Scott Emerson, Milana Ivkovic, Nia C Jenkins, Christopher Lübker, Muhammad Mamdani, Thomas Padgett, Luc Van Gaal, Peter E Weeke and 1 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in PharmacoEconomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Martin BøgNovo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark. AXBQ@novonordisk.com.ORCID http://orcid.org/0000-0001-6431-8307
Anders Bo BojesenNovo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark.
Scott EmersonUniversity of Washington, Seattle, WA, USA.
Milana IvkovicNovo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark.
Nia C JenkinsHealth Economics and Outcomes Research Ltd., Cardiff, UK.
Christopher LübkerNovo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark.
Muhammad MamdaniUnity Health Toronto, Toronto, ON, Canada.
Thomas PadgettHealth Economics and Outcomes Research Ltd., Cardiff, UK.
Luc Van GaalUniversity Hospital Antwerp, Antwerp, Belgium.
Peter E WeekeNovo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark.
A Michael LincoffDepartment of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOverweight and obesity is a prevalent and growing global health concern associated with a significant healthcare burden. With recent advancements in weight management interventions demonstrating cardioprotective benefits, there is a need for risk equations that can accurately predict cardiovascular event risk in health economic models to support healthcare decision making and resource allocation.

objectiveWe aimed to derive risk equations using SELECT trial data that estimate the risk of acute coronary syndrome and stroke in people with established cardiovascular disease and overweight or obesity but without diabetes mellitus for use in health economic modelling.

methodsRisk equations estimating first in-trial observed acute coronary syndrome and stroke were derived from patient-level data from the SELECT trial, a double-blind randomised placebo-controlled trial comparing semaglutide 2.4 mg with placebo. Risk factors were identified from the literature and by clinical experts. Risk equations were developed using cause-specific Cox proportional hazard models with all-cause mortality as a competing risk. Least absolute shrinkage and selection operator (LASSO) penalisation was applied 100 times in bootstrap samples to refine the risk equations. Final risk equations were validated with clinical experts and using SELECT trial data.

resultsSex, coronary heart disease, a history of acute coronary syndrome and use of angina medications had the strongest associations with acute coronary syndrome (hazard ratio 1.67-1.82). For stroke, a history of atrial fibrillation, cerebrovascular disorder, stroke and transient ischaemic attack had the strongest associations (hazard ratio 1.40-1.70). In terms of discrimination, the risk equations had an area under the receiver operating characteristic curve (AUC) of 0.66-0.68 for acute coronary syndrome and 0.68-0.71 for stroke, and C-indices of 0.67-0.69 for acute coronary syndrome and 0.66-0.69 for stroke. The risk equations showed good cohort-level predictive capabilities over a 4-year time horizon.

conclusionsThese novel, treatment-specific, trial-derived risk equations are the first to predict the risk of secondary cardiovascular events in people with overweight or obesity and established cardiovascular disease but without diabetes. Incorporating these risk equations into health economic models may improve the accuracy of economic evaluations in this population.

Indexed as

Acute Coronary SyndromeCardiovascular DiseasesModels, EconomicObesityOverweightStrokeAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedProportional Hazards ModelsRisk AssessmentRisk FactorsSemaglutideSemaglutide

Identifiers

PMID41553702
PMCPMC12916528

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.